NCOA3
Overview
NCOA3 (Nuclear Receptor Coactivator 3, also known as AIB1 or SRC-3) encodes a transcriptional coactivator of nuclear hormone receptors and is involved in steroid-responsive gene regulation. It is amplified or overexpressed in several epithelial cancers, including breast and prostate cancers. In urothelial carcinoma, NCOA3 was identified as a sub-clonal mutation in a primary tumor that became enriched in chemotherapy-resistant metastatic lesions, implicating it as a candidate driver of clonal evolution under platinum-based chemotherapy selection pressure.
Alterations observed in the corpus
- Sub-clonal mutation in the WCM117 urothelial carcinoma primary that became enriched in chemotherapy-treated metastatic lesions, representing an early founder signal that survived platinum-based chemotherapy selection PMID:27749842
Cancer types (linked)
- BLCA: sub-clonal NCOA3 mutation detected in the pre-chemotherapy primary of patient WCM117 in the Weill Cornell cohort (n=32 patients, 72 tumors); enrichment in post-chemotherapy metastases observed by whole-exome sequencing PMID:27749842
Co-occurrence and mutual exclusivity
- Detected alongside sub-clonal mutations in RYR2, ANKRD62, and LSS in the WCM117 primary tumor founder clone that expanded under chemotherapy selection PMID:27749842
Therapeutic relevance
- No direct therapeutic targeting reported in the corpus for UC. NCOA3/AIB1 is under investigation as a target in breast cancer but no linked therapeutic data for bladder cancer appears in this corpus.
Open questions
- Whether NCOA3 mutation is a passenger or driver of chemotherapy resistance in UC remains unresolved; functional validation in urothelial carcinoma models has not been presented.
Sources
This page was processed by entity-page-writer on 2026-05-15.